Company insider dossier

MediciNova Inc insider intelligence

MNOV filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.

Terminal chart Weekly report Factor intelligence Healthcare Biotechnology Data API
50/100

No directional read

18/100 confidence
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Latest evidence
23 Jun 2026

Investment committee read

No directional read

The tape contains filings, but none provide enough priced common-share evidence for a directional classification.

Evidence is contextual

Evidence in favour

  • Participation spans 3 named insiders rather than one filing source.

Decision risks

  • Most filings are awards, derivatives, unpriced common shares, or other securities and remain contextual.
Conviction50No directional read
Confidence18Thin evidence
Named insiders3participating in the tape
Controlled events0directional common-share events
Acquisition value$0normalized amount
Disposal value$0normalized amount

Price confirmation map

Weekly price with common-share events

Acquisitions and disposals are aligned to the nearest completed weekly bar.

1.861.701.541.391.23
Mar 2025Sep 2026
Weekly closeCommon-share acquisitionCommon-share disposal

Market confirmation

Price and trend context

Latest close
1.81 USD
One-week move
+11.0%
Four-week move
+38.2%
Fair-value gap
+18.3%
Trend signal
Active
Relative strength
14.3

Directional balance

Controlled event mix

0%acquisition
Acquisition events
0
Disposal events
0
Net value
$0

Cadence

Twelve-week filing pressure

Volume shows attention. Controlled events determine direction.

029 Jun
006 Jul
013 Jul
020 Jul
027 Jul
003 Aug
010 Aug
017 Aug
024 Aug
031 Aug
007 Sep
014 Sep

Named participants

Insider conviction by person

BEAVER, CAROLYNDirector500 events
LEMEROND, NICOLEDirector500 events
NAGAO, HIDEKIDirector500 events

Evidence quality

Security and transaction context

Common equity0
Equity compensation0
Options and derivatives3
Other securities0

Role architecture

Who is participating

Director3

Transaction evidence

Auditable MNOV filing ledger

Showing 1 to 3 of 3.

BEAVER, CAROLYNDirector
AcquisitionOptions and derivatives
44500 sharesStock Option (Right to Buy)
Not reportedContext evidence
LEMEROND, NICOLEDirector
AcquisitionOptions and derivatives
44500 sharesStock Option (Right to Buy)
Not reportedContext evidence
NAGAO, HIDEKIDirector
AcquisitionOptions and derivatives
44500 sharesStock Option (Right to Buy)
Not reportedContext evidence

Reading the dossier

Direction and confidence are separate

Conviction

The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.

Confidence

Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.

Disposals

Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.

Price confirmation

The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context